Rezolute shares rise 10.24% intraday after CFO Daron Evans buys 21% more shares, signaling insider confidence.

Rezolute surged 10.24% intraday after announcing insights from its Phase 3 sunRIZE study in congenital hyperinsulinism and findings from its expanded access program in tumor hyperinsulinism. The update, released 16 days prior, highlighted data from its late-stage trial and real-world evidence, signaling potential therapeutic value despite earlier Phase 3 failures. This recent development, coupled with ongoing interest in its KLKB1 inhibitor pipeline, appears to have driven renewed investor optimism, offsetting prior concerns over the drug’s efficacy. The stock’s intraday rebound follows a month marked by significant declines due to the sunRIZE trial’s primary endpoint miss and broader market skepticism.